Continued Treatment with Parsaclisib for Blood Disorders

We are providing ongoing treatment for patients who have previously participated in studies of parsaclisib. The goal is to evaluate the safety of this medication alone or with other therapies.

≤5 visits Efficacy phase (II)Post-Trial Drug Access No Placebo Cost Reimbursement Partially Remote Investigational Medicines Oral InjectionHematologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Imbruvica

Imbruvica is a medicine used to treat certain types of blood cancers, including some forms of lymphoma and leukemia.

Jakavi

Jakavi is a medicine used to treat certain serious blood disorders that affect bone marrow and blood cell production.

Minjuvi

Minjuvi is a cancer medicine used to treat certain types of non-Hodgkin lymphoma in adults.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Ibrutinib

Ibrutinib is a substance that targets immune cell signaling to treat certain blood cancers, such as chronic lymphocytic leukemia and mantle cell lymphoma.

Ruxolitinib

Ruxolitinib is a substance that blocks cell signals to reduce abnormal blood cell growth and inflammation in certain bone marrow disorders.

Tafasitamab

Tafasitamab is a targeted antibody that helps the immune system attack B-cell cancers, particularly some types of non-Hodgkin lymphoma.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Parsaclisib

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Opzelura

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

UZ Leuven

Hematologie

Heverlee, Belgium

Universitair Ziekenhuis Gent

Hematologie

Ledeberg, Belgium

Cliniques Universitaires Saint-Luc

Hematology Department

Sint-Stevens-Woluwe, Belgium

Sponsor: Incyte Corp.

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.